Search

Displaying results 1931 - 1940 of 10000 in total
  1. Drug

    Tetrachlorodecaoxide

    go.drugbank.com/drugs/DB05389
    Approved

    The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. … WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Coagulation factor X human

    go.drugbank.com/drugs/DB13148
    ApprovedInvestigational

    However its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency. … While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways.

    Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET
  3. Drug

    Polyethylene glycol 400

    go.drugbank.com/drugs/DB11077
    ApprovedInvestigational

    It is used in ophthalmic solutions for the relief of burning, irritation and/or discomfort that follows dryness of the eye [L1785]. … It is very hydrophilic, which renders it a useful ingredient in drug formulations to augment the solubility and bioavailability of weakly water-soluble drugs.

    Mixtures: i-Drops LUBRICANT EYE DROPS, i-Drops LUBRICANT EYE DROPSCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Zylonta also received approval in the EU on December 22, 2022. … [L45206] This therapy was developed by ADC Therapeutics and its accelerated approval for relapsed or refractory B-cell lymphoma is based on promising results from the LOTIS-2 clinical trial.

  5. Drug

    Denileukin diftitox

    go.drugbank.com/drugs/DB00004
    ApprovedInvestigational

    approved to treat a human disease in the US. … [A264344] In 2014, it was withdrawn voluntarily from the market due to manufacturing issues; however, the biologics license application (BLA) for denileukin diftitox was resubmitted, and it was approved

    Synonyms: N-MET-187-HIS-388-ALA-1-388-TOXIN (CORYNEBACTERIUM DIPHTHERIAE C7) WITH 1-133-INTERLEUKIN 2, N-L-METHIONYL-387-L-HISTIDINE-388-L-ALANINE-1-388-TOXIN (CORYNEBACTERIUM DIPHTHERIAE STRAIN C7) (388->2') PROTEIN WITH 2-133-INTERLEUKIN 2 (HUMAN CLONE PTIL2-21A)
  6. Drug

    Clofarabine

    go.drugbank.com/drugs/DB00631
    ApprovedInvestigational

    Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. … It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.

    Synonyms: 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine, 2-chloro-9-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)adenine
  7. Indication

    Testosterone Deficiency

    go.drugbank.com/conditions/DBCOND0034483
    Drugs: Methyltestosterone · Testosterone propionate
    Synonyms: Testosterone dec
  8. Drug

    Pyrethrum extract

    go.drugbank.com/drugs/DB11087
    Approved

    The active compound is absorbed by the lice and destroys them by acting on their nervous systems but is thought to exert minimal effect on humans. … Pyrethrum extract is also used used to treat head, body, and pubic lice infections.

    Mixtures: El piojito Lice Killing, Dg Health Lice Killing Maximum StrengthCategories: Compounds used in a research, industrial, or household setting
  9. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one … Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.

  10. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. … [L47765] Talquetamab binds to GPRC5D, a cell surface receptor expressed predominantly on multiple myeloma cells, and CD3 on T cells.

    Synonyms: ANTIBODY; BISPECIFIC GAMMA4 HEAVY CHAIN HUMANIZED AN, IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL